Ocular Therapeutix OCUL Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$265.94M-37.4% | -$193.51M-140% | -$80.74M-13.7% | -$71.04M-984% | ||
| $4.32M+14.2% | $3.79M+26.9% | $2.98M+41.4% | $2.11M-12.9% | ||
| $43.18M+30.4% | $33.11M+85.7% | $17.83M+5.1% | $16.96M+13.3% | ||
| $3.4M-9.0% | $3.73M-38.8% | $6.11M+25.8% | $4.85M+4.9% | ||
| —— | —— | —— | —— | ||
| —— | $6.21M— | —— | $190K-97.9% | ||
| $524K— | —— | —— | $724K+1,378% | ||
| -$887K— | —— | $583K— | —— | ||
| $5.25M— | —— | —— | —— | ||
| —— | $5.66M+44.5% | $3.92M— | —— | ||
| —— | -$262K— | —— | —— | ||
| -$1.66M-39.7% | -$1.19M+34.6% | -$1.81M-166% | $2.73M+301% | ||
| -$204.88M-52.1% | -$134.68M-91.8% | -$70.23M-17.8% | -$59.6M+9.1% | ||
| $12.01M+832% | $1.29M-78.8% | $6.09M+63.8% | $3.72M+211% | ||
| -$11.88M-822% | -$1.29M+78.8% | -$6.09M-63.8% | -$3.72M-211% | ||
| $20.54M— | —— | $117.26M+22,713% | $514K— | ||
| $561.72M+69.1% | $332.11M+95.6% | $169.83M+11,580% | $1.45M-49.0% | ||
| $344.96M— | —— | $93.51M+251% | -$61.86M+3.2% | ||
| $9.03M-58.1% | $21.53M+294% | $5.46M+154% | $2.15M+11.1% | ||
| $3.4M-9.0% | $3.73M-38.8% | $6.11M+25.8% | $4.85M+4.9% | ||
| —— | —— | -$5.19M— | —— | ||
| -$1.36M— | —— | -$1.57M-149% | $3.18M+425% | ||
| -$1.66M-39.7% | -$1.19M+34.6% | -$1.81M-166% | $2.73M+301% | ||
| —— | $5.66M+44.5% | $3.92M— | —— | ||
| —— | —— | —— | $1.38M— | ||
| -$1.66M-39.7% | -$1.19M+34.6% | -$1.81M-166% | $2.73M+301% | ||
| —— | —— | —— | —— | ||
| -$216.89M-59.5% | -$135.97M-78.1% | -$76.32M-20.5% | -$63.32M+5.1% | ||
| -$216.89M-59.5% | -$135.97M-78.1% | -$76.32M-20.5% | -$63.32M+5.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Ocular Therapeutix generate?
- Ocular Therapeutix (OCUL) generated -$226.2M in operating cash flow over the trailing twelve months.
- What is Ocular Therapeutix's free cash flow?
- After $14.7M of capital expenditures, Ocular Therapeutix's free cash flow was -$240.9M over the trailing twelve months, down 62.3% year over year.
- Where does Ocular Therapeutix's cash flow data come from?
- Every line is extracted from Ocular Therapeutix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
